香港联交所最新资料显示，8月29日，执行董事赵新礼增持高视医疗(02407)5900股，每股作价7.37港 元，总金额约为4.35万港元。增持后最新持股数目约为364.49万股，最新持股比例为2.46%。 ...

智通财经APP获悉，香港联交所最新资料显示，8月29日，执行董事赵新礼增持高视医疗(02407)5900 股，每股作价7.37港元，总金额约为4.35万港元。增持后最新持股数目约为364.49万股，最新持股比例 为2.46%。 ...

Summary of the Conference Call for Gaoshi Medical Company Overview - **Company**: Gaoshi Medical - **Industry**: Medical Devices, specifically Ophthalmology Key Financial Performance - Total revenue for H1 2025 reached **653 million RMB**, a **1.7%** increase year-on-year from **642 million RMB** in the same period last year [2][3] - Gross profit was **316 million RMB**, with a gross margin of **48.4%**, up **1.8 percentage points** year-on-year [3] - Net profit amounted to **35.9 million RMB**, reflecting a **33.5%** increase year-on-year [2][3] Revenue Breakdown - **Self-owned business revenue**: **322 million RMB**, accounting for **49%** of total revenue, with a significant contribution from artificial lenses [2][4] - Artificial lens revenue: **170 million RMB**, up **11.4%** year-on-year [4] - Mid-to-high-end lens growth: **25.1%** [4] - **Distribution business revenue**: **327 million RMB**, down **6.8%** year-on-year, representing **51%** of total revenue [2][7] - **Overseas market revenue**: **171 million RMB**, a **17.6%** increase year-on-year, accounting for **26.2%** of total revenue [2][9] Product and Service Developments - **Technical services revenue**: **119 million RMB**, up **8.3%** year-on-year, with an engineering team of **135 members** and **14,000 service instances** [2][6] - New partnerships and products introduced, including the Heidelberg three-in-one ophthalmic diagnostic platform and Sirin's all-laser surgical system [7] - R&D investment reached **43.4 million RMB**, a **23.6%** increase year-on-year, representing **6.6%** of total revenue [2][10] Market Strategy and Future Plans - Focus on **13 global mid-to-high-end lens markets**, transitioning to a direct sales model, with Brazil expected to launch three series by year-end [2][9][12] - Plans to enhance product lines with new registrations for various self-owned products, including **ultrasonic phacoemulsification devices** and **OK lenses** [12][24] - Emphasis on increasing the coverage of high-end lenses in the Chinese market while expanding internationally [17][18] Competitive Advantages - Strong performance in the domestic artificial lens market, with a **80%** increase in multi-focal and toric lens implantations [15][16] - Strategic positioning to leverage the national procurement policy to enhance product penetration and market share [18][19] Cash Flow and Debt Management - Significant improvement in operating cash flow due to increased cash receipts from sales and reduced procurement costs [13] - Debt structure improved following the repayment of a merger loan [13] Investor Relations and Communication - Plans for investor engagement through open days in Wuxi or Shenzhen to discuss corporate culture, core products, and market strategies [34][35] Industry Trends - The ophthalmology industry has seen rapid growth post-pandemic, with increasing domestic replacements and new entrants in the medical device sector [32] - Gaoshi Medical is positioned to benefit from advancements in supply chains and talent systems within the industry [32][33] Conclusion Gaoshi Medical demonstrates robust financial growth, strategic market positioning, and a commitment to innovation in the ophthalmology sector, with plans for continued expansion and investor engagement in the coming years.

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02407 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 USD | | 0.0001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000 USD | | 0.0001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 高视医疗科技有 ...

Group 1 - The company Gaoshi Medical (02407) announced that as of August 28, 2025, Mr. Gao Tieta, the chairman of the board and executive director, will no longer serve as a member of the nomination committee [1] - Ms. Li Wenqi, an executive director, has been appointed as a member of the nomination committee [1]

Group 1 - The company announced that starting from August 28, 2025, the current chairman and executive director, Mr. Gao Tieta, will no longer serve as a member of the nomination committee [1] - Executive director Ms. Li Wenqi has been appointed as a member of the nomination committee [1]

Group 1 - The core point of the article is that Gaoshi Medical (02407.HK) announced a change in its nomination committee to comply with new gender diversity regulations under the securities listing rules [1] - Starting from August 28, 2025, the chairman and executive director, Gao Tieta, will no longer serve as a member of the nomination committee [1] - Executive director Li Wenqi has been appointed as a member of the nomination committee to meet the new requirements [1]

Core Viewpoint - The company reported a revenue of RMB 653 million for the six months ending June 30, 2025, representing a year-on-year increase of 1.7% and a net profit of RMB 35.9 million, which is a 33.5% increase compared to the same period in 2024 [1] Revenue Breakdown - The revenue primarily came from two sources: (i) sales of ophthalmic medical devices and consumables, and (ii) provision of technical services [1] Market Performance - The company's ability to maintain revenue growth in a persistently weak global economic environment is attributed to the expansion in overseas markets and the synergistic effect of increased revenue from proprietary products [1]

高视医疗(02407)发布截至2025年6月30日止6个月中期业绩，集团收入人民币6.53亿元，同比增加1.7%; 净利润3589.4万元，同比增长33.3%;每股盈利0.26元。 ...

Group 1 - The core viewpoint of the article is that Gaoshi Medical (02407) reported its interim results for the six months ending June 30, 2025, showing a slight increase in revenue and a significant rise in net profit [1] Group 2 - The company's revenue reached RMB 653 million, representing a year-on-year increase of 1.7% [1] - The net profit for the period was RMB 35.894 million, which reflects a year-on-year growth of 33.3% [1] - Earnings per share were reported at RMB 0.26 [1]